English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 3.5 |
| Open | 3.43 |
| 1-Year Change | 55.91% |
| Day's Range | 3.28 - 3.49 |
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing, and marketing products to treat psychiatric disorders. Its primary product includes NeuroStar Advanced Therapy System, which is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS), to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat depressive disorder. The Company sells NeuroStar Advanced Therapy System and recurring treatment Sessions in the United States.
BRIEF: For the fiscal year ended 31 December 2021, Neuronetics Inc revenues increased 12% to $55.3M. Net loss increased 14% to $31.2M. Revenues reflect United States segment increase of 12% to $53.4M, International segment increase of 8% to $1.9M. Higher net loss reflects Sales and marketing - Balancing value increase of 16% to $35.7M (expense), General and administrative - Balancing increase of 24% to $20.1M (expense).
